NeuraClick Expands Scientific and Translational Leadership with Key Advisory Appointments
This image was generated by AI and may not depict real events.
NeuraClick, a biopharmaceutical company, has appointed two new advisors to strengthen its scientific and translational capabilities. The appointments of Dr. Gavin Dawe and Dr. Tomi Sawyer will help guide the company's development of macrocyclic neuropeptide therapeutics for central nervous system and neuro-metabolic disorders.
NeuraClick, a preclinical-stage biopharmaceutical company, has expanded its scientific and translational leadership. The company appointed Dr. Gavin Dawe as Scientific Advisor and Dr. Tomi Sawyer as Strategic Advisor. Dr. Dawe is a leading neuropharmacologist and translational neuroscientist, while Dr. Sawyer is a globally recognized leader in peptide and macrocycle drug discovery. They will help guide the company's development of macrocyclic neuropeptide therapeutics. The appointments strengthen NeuraClick's capabilities as it advances its platform and lead programs. The company is developing therapeutics for central nervous system and neuro-metabolic disorders.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.